| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA979: Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation |
|
Medicine details |
|
| Medicine name | ivosidenib (Tibsovo®) |
| Formulation | 250 mg film-coated tablet |
| Reference number | 3680 |
| Indication | Treatment of acute myeloid leukaemia (AML), isocitrate dehydrogenase-1 (IDH1) mutation, first-line combination with azacitidine |
| Company | Servier Laboratories Limited |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 08/04/2024 |
| NICE guidance | TA979: Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation |